Related Experiment Video

Updated: Jun 8, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

KRAS inhibitors in drug resistance and potential for combination therapy

Lala S Rathod, Nikhil S Sakle, Santosh N Mokale

    Tumori
    |November 7, 2024
    PubMed

    Insights

    Kirsten Rat Sarcoma (KRAS) inhibitors show promise for lung cancer but face resistance. This review explores combination therapies to overcome resistance and improve treatment efficacy for KRAS mutations.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • Kirsten Rat Sarcoma (KRAS) proteins are crucial signaling hubs regulating cell functions.
    • KRAS mutations drive various cancers, making them significant therapeutic targets.
    • Recent FDA approval of KRASG12C inhibitors offers new treatment avenues for metastatic lung cancer.

    Purpose of the Study:

    • To review strategies for overcoming acquired resistance to covalent KRASG12C inhibitors.
    • To highlight the importance of developing therapies for other common KRAS mutations like KRASG12D and KRASG12V.
    • To explore the potential of combination treatments to enhance the efficacy of KRAS inhibitors.

    Main Methods:

    • Review of current clinical studies and preclinical research on KRASG12C inhibitors.
    • Analysis of resistance mechanisms encountered in clinical settings.
    • Exploration of combinatorial therapeutic approaches.

    Main Results:

    • Clinical resistance to KRASG12C inhibitors is a significant challenge.
    • Combination therapies are being investigated to improve treatment outcomes.
    • KRASG12D and KRASG12V mutations represent a substantial unmet need.

    Conclusions:

    • Overcoming resistance is critical for the long-term success of KRAS-targeted therapies.
    • Combination strategies hold promise for enhancing the activity of KRASG12C inhibitors.
    • Continued research into KRASG12D and KRASG12V targeted therapies is essential.
    Keywords:
    KRASG12C inhibitorsKRASG12D reversible inhibitorsMTRX1133adagrasibcombination therapyresistancesotorasib

    More Related Videos

    Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

    Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

    Published on: December 9, 2015

    10.5K
    Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

    Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

    Published on: December 11, 2017

    7.2K

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    4.9K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.3K
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    4.7K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.5K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    6.4K
    Combined Effects of Drugs: Synergism01:27

    Combined Effects of Drugs: Synergism

    Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
    Such synergistic combinations...
    3.7K